Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612

被引：0
|
作者：
Birnberg, T. [1 ]
Adar, L. [1 ]
Poewe, W. [2 ]
Nyholm, D. [3 ]
Bjornsson, M. [4 ]
Karlsson, M. [4 ]
机构：
[1] NeuroDerm, Rehovot, Israel
[2] Med Univ Innsbruck, Innsbruck, Austria
[3] Uppsala Univ, Uppsala, Sweden
[4] Pharmetheus, Uppsala, Sweden
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-363
引用
收藏
页码：608 / 608
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Bjornsson, M.
    Karlsson, M.
    MOVEMENT DISORDERS, 2021, 36 : S162 - S162
  • [2] The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
    LeWitt, Peter A.
    Stocchi, Fabrizio
    Arkadir, David
    Caraco, Yoseph
    Adar, Liat
    Perlstein, Itay
    Case, Ryan
    Giladi, Nir
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [3] Continuous Administration of Subcutaneous Levodopa/Carbidopa (ND0612) Demonstrated Comparable Levodopa Pharmacokinetics to Levodopa/Carbidopa Intestinal Gel (LCIG)
    Adar, Liat
    Minei, Tamar Rachmilewitz
    Cohen, Yael
    Oren, Sheila
    NEUROLOGY, 2017, 88
  • [4] Relative bioavailability of levodopa given as a subcutaneous infusion with ND0612 versus oral IR levodopa/carbidopa
    Adar, L.
    Vostokova, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 165 - 165
  • [5] Enrolment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612
    Rascol, O.
    Albanese, A.
    Ellenbogen, A.
    Ferreira, J.
    Gurevich, T.
    Hassin, S.
    Hernandez-Vara, J.
    Isaacson, S.
    Kieburtz, K.
    LeWitt, P.
    Manzanares, L. Lopez
    Olanow, C.
    Pahwa, R.
    Poewe, W.
    Sarva, H.
    Stocchi, F.
    Yardeni, T.
    Adar, L.
    Salin, L.
    Lopes, N.
    Sasson, N.
    Case, R.
    Espay, A.
    Giladi, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 708 - 709
  • [6] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
    Adar, Liat
    Vostokova, Natalia
    NEUROLOGY, 2023, 100 (17)
  • [7] Quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study
    Espay, Alberto
    Yardeni, Tami
    Adar, Liat
    Case, Ryan
    Poewe, Werner
    Isaacson, Stuart
    MOVEMENT DISORDERS, 2023, 38 : S16 - S16
  • [8] Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes
    Ellenbogen, Aaron
    Stocchi, Fabrizio
    Espay, Alberto
    Poewe, Werner
    Oren, Sheila
    Case, Ryan
    Olanow, C. Warren
    NEUROLOGY, 2020, 94 (15)
  • [9] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
    Adar, L.
    Vostokova, N.
    MOVEMENT DISORDERS, 2022, 37 : S438 - S439
  • [10] Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: findings from the ND0612 BeyoND study
    Poewe, W.
    Stocchi, F.
    Adar, L.
    Yardeni, T.
    Espay, A.
    MOVEMENT DISORDERS, 2022, 37 : S347 - S347
12345